Viridian Therapeutics Inc (VRDN) - Total Liabilities
Based on the latest financial reports, Viridian Therapeutics Inc (VRDN) has total liabilities worth $153.01 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Viridian Therapeutics Inc (VRDN) equity growth momentum to track the company's year-over-year net asset growth rate.
Viridian Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Viridian Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Viridian Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.
Viridian Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Viridian Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pegasus Hava Tasimaciligi AS
IS:PGSUS
|
Turkey | TL5.66 Billion |
|
Yusys Technologies Co Ltd Class A
SHE:300674
|
China | CN¥1.55 Billion |
|
Tibet Summit Resources Co Ltd
SHG:600338
|
China | CN¥2.28 Billion |
|
TX Group AG
SW:TXGN
|
Switzerland | CHF797.00 Million |
|
Huntsman Corporation
NYSE:HUN
|
USA | $4.23 Billion |
|
Essity AB (publ)
ST:ESSITY-A
|
Sweden | Skr92.70 Billion |
|
Companhia Siderurgica Nacional ADR
NYSE:SID
|
USA | $15.67 Billion |
|
IBI Inv House
TA:IBI
|
Israel | ILA972.93 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Viridian Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Viridian Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Viridian Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Viridian Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Viridian Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $177.25 Million | +150.48% |
| 2024-12-31 | $70.76 Million | +46.20% |
| 2023-12-31 | $48.40 Million | +20.92% |
| 2022-12-31 | $40.03 Million | +150.28% |
| 2021-12-31 | $15.99 Million | +42.57% |
| 2020-12-31 | $11.22 Million | -22.68% |
| 2019-12-31 | $14.51 Million | -1.99% |
| 2018-12-31 | $14.80 Million | +5.96% |
| 2017-12-31 | $13.97 Million | +204.71% |
| 2016-12-31 | $4.58 Million | +83.99% |
| 2015-12-31 | $2.49 Million | +18.78% |
| 2014-12-31 | $2.10 Million | +27.45% |
| 2013-12-31 | $1.65 Million | -93.20% |
| 2012-12-31 | $24.22 Million | -- |
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develo… Read more